

| Package | Price per Dose | Price | |
|---|---|---|---|
| 360 pills | £0.57 | £255.58 £204.46 Free shipping | |
| 180 pills | £0.62 | £140.56 £112.45 | |
| 120 pills | £0.70 | £105.06 £84.05 | |
| 90 pills | £0.75 | £83.76 £67.01 | |
| 60 pills | £0.81 | £61.04 £48.84 | |
| 30 pills | £0.87 | £32.64 £26.12 | |
| 360 pills | £0.68 | £306.70 £245.36 Free shipping | |
| 180 pills | £0.74 | £166.12 £132.90 | |
| 120 pills | £0.80 | £119.26 £95.41 | |
| 90 pills | £0.86 | £96.54 £77.23 | |
| 60 pills | £0.97 | £72.40 £57.92 | |
| 30 pills | £1.11 | £41.16 £32.93 | |
| 360 pills | £0.76 | £342.19 £273.76 Free shipping | |
| 180 pills | £0.90 | £201.62 £161.30 Free shipping | |
| 120 pills | £1.02 | £153.34 £122.67 | |
| 90 pills | £1.14 | £127.78 £102.23 | |
| 60 pills | £1.15 | £86.60 £69.28 | |
| 30 pills | £1.22 | £45.42 £36.34 | |
| 20 pills | £1.28 | £32.64 £26.12 | |
| 10 pills | £1.29 | £15.61 £12.48 |
Warfarin was discovered in 1948 as a synthetic anticoagulant after researchers linked spoiled sweet clover hay to fatal bleeding in cattle; today it remains one of the most widely used oral anticoagulants worldwide. It exerts its effect by inhibiting the vitamin K epoxide reductase complex, which lowers the production of clotting factors II, VII, IX, and X, as well as regulatory proteins C and S. This mechanism creates a controlled, time-dependent reduction in blood-clotting potential, rather than an immediate shutoff of coagulation.
As a drug with a narrow therapeutic window, Warfarin requires ongoing blood monitoring and careful dose tailoring. Its anticoagulant effect is influenced by diet (especially vitamin K-rich foods), interactions with numerous medications, and individual genetic variation in metabolism and target enzymes. In clinical practice, dosing aims to achieve a target INR that balances stroke prevention with bleeding risk, while events such as illness or changes in weight can shift the required dose.
Pharmacologically, Warfarin belongs to the vitamin K antagonist class. Dosing is typically once daily, with gradual adjustment based on INR results. The agent’s long history provides a robust body of evidence across diverse conditions, though newer agents offer different pharmacokinetic profiles that some patients may prefer for convenience or predictable effects.
Within the vitamin K antagonist family, Warfarin sits alongside other historical agents such as acenocoumarol and phenprocoumon. Acenocoumarol has a shorter half-life, leading to more rapid changes in anticoagulation with dose adjustments or missed doses; phenprocoumon and similar compounds tend to have longer durations of action, requiring careful planning around emergencies or surgery. These differences can influence how quickly a patient’s INR fluctuates and how reversals are managed.
Genetic variation, especially in VKORC1 and CYP2C9, meaningfully affects Warfarin metabolism and dose needs for many individuals. Some patients may benefit from genotype-guided dosing, though routine testing is not universally adopted. In contrast, the newer direct oral anticoagulants (DOACs) do not rely on vitamin K pathways and typically do not require routine INR monitoring, highlighting a trade-off between historical experience and modern predictability.
Dietary interactions remain a hallmark of Warfarin therapy. Large shifts in vitamin K intake can alter INR and necessitate dose changes, a factor less pronounced with some DOACs. Clinicians weigh these considerations, along with patient preference, kidney function, and bleeding risk, when choosing an anticoagulant in a given situation.
Warfarin is indicated for preventing stroke and systemic embolism in nonvalvular atrial fibrillation and atrial flutter, particularly when other risk factors are present. It also treats and prevents venous thromboembolism (DVT and PE) and provides protection after certain orthopedic or cardiac procedures where clot risk is high.
In patients with mechanical heart valves, Warfarin remains a mainstay of lifelong anticoagulation, with dosing guided by a specialist and a careful monitoring schedule. Around procedures, bridging with short-acting anticoagulants such as heparin is sometimes employed to maintain protection while minimizing bleeding risk. Dose stability and regular INR checks are essential for long-term success.
Contraindications include active bleeding, severe liver disease, pregnancy (due to teratogenic risk), and certain drug interactions. Treatments for acute bleeding or overdose rely on vitamin K and rapid reversal strategies, underscoring the importance of clear patient education and access to urgent care.
To illustrate practical differences, consider Warfarin alongside two commonly used direct oral anticoagulants (DOACs): apixaban and rivaroxaban. The table below highlights core contrasts in mechanism, monitoring, reversibility, dietary considerations, and typical indications.
| Medication | Mechanism | Monitoring | Reversal options | Dietary considerations | Typical indications |
|---|---|---|---|---|---|
| Warfarin | Vitamin K antagonist; inhibits synthesis of II, VII, IX, X | INR required regularly | Vitamin K, PCC/FFP | Significant interaction with vitamin K–rich foods | Stroke prevention in AF, VTE treatment, mechanical valves |
| Apixaban | Direct factor Xa inhibitor | No routine coagulation monitoring for most patients | Andexanet alfa (and others for specific cases); caution with bleeding | Minimal dietary interaction | Stroke prevention in AF, treatment of DVT/PE (initial and continuation) |
| Rivaroxaban | Direct factor Xa inhibitor | Not routinely monitored; sometimes used in clinical help for adherence | Andexanet alfa variant for reversal | Limited dietary restriction | Stroke prevention in AF, VTE treatment/prophylaxis |
In practice, Warfarin offers a long track record and a robust reversal framework, but it requires ongoing INR monitoring and attention to drug–food interactions. DOACs provide more predictable pharmacokinetics with less routine testing, though they may be less flexible in reversal and can be costlier or limited by kidney function and certain medical devices.
Bleeding risk is the central safety consideration with Warfarin. The likelihood of major bleeding increases with higher INRs, older age, concomitant antiplatelet therapy, and certain illnesses. Patients should be educated to recognize warning signs such as unusual bruising, blood in urine or stool, or severe headaches, and to seek prompt medical attention if needed.
Drug–drug interactions are common, including antibiotics, antifungals, antifibrinolytics, and some herbal supplements. Dietary consistency regarding vitamin K is advised to avoid abrupt INR swings. Regular monitoring, careful dose adjustments, and clinical assessments help balance protection from clotting with bleeding risk.
When reversing Warfarin for procedures or emergencies, providers may use vitamin K alone or with plasma products to restore clotting factor activity swiftly. Patients with stable, well-managed Warfarin therapy generally experience favorable outcomes, but individualized plans remain essential to address comorbidities, concurrent medications, and life events that can shift anticoagulation needs.
14–21 days. Free from £151.46 .
5–9 days. £22.72
−10% when paying with cryptocurrency.
−10% on all repeat orders.
All orders are packed in neutral, unbranded boxes with no product name on the outside.
